Efficacy and safety of Tribulus teresteris in female sexual disorder

Phase 2

• Conditions: Female sexual disease.; Sexual dysfunction not caused by organic disorder or disease

• Registration Number: IRCT2012111111425N1
• Lead Sponsor: Dr. Minaei; Vice chancellor for research Traditional Medicine Faculty of Tehran University of Medica

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

Fixed partner; Persistent or intermittent low libido; A normal pelvic examination; A normal pap smear; A normal breast examination.
Exclusion criteria: No fixed partner; A serious medical situation; History of genital or breast cancer; An under observed depression or other psychological disorders

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ibido. Timepoint: At the begining of the trial, 7th day and one month after end of the drug. Method of measurement: FSFI questionaire.

Secondary Outcome Measures

Name	Time	Method
Arousal. Timepoint: At the beginning of the study, 7 days after starting the drug and one month after finishing the drug. Method of measurement: FSFI questionnaire.;Desire. Timepoint: In the beginning of study, 7 days after it and 1 month after finishing the drug. Method of measurement: FSFI questionnaire.;Satisfaction. Timepoint: At the beginning of the study, 7days after it and 1 month after finishing the drug. Method of measurement: FSFI questionnaire.;Orgasm. Timepoint: At the beginning of the study, 7 days after it and 1 month after finishing the drug. Method of measurement: FSFI questionnaire.;Dysparonia. Timepoint: At the beginning of the study, 7 days after it and 1 month after finishing the drug. Method of measurement: FSFI questonnaire.